Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.
(2012) In EJD. European Journal of Dermatology 22(2). p.238-245- Abstract
- Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€,... (More)
- Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€, light therapy (LT; 24%) 1,274€, traditional systemic treatment (TST; 26%) 1,085€ and biological systemic treatment (BST; 16%) 1,709€ per patient-month. Main cost drivers were: outpatient visits (56%) in TT as well as for LT (78%), productivity loss (40%) in TST, and biological drugs (71%) among BST patients. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. Conclusions: The one-month cost-of-illness amounted to almost 1,000€/month, with great variations. Despite 1,190€ difference in drug cost for TST vs BST, total cost per month differed by 623€ because of offsets from improved productivity. A trend towards lower severity and reductions in outpatient and topical treatment costs was seen. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2432544
- author
- Ghatnekar, Ola ; Ljungberg, Anders ; Wirestrand, Lars-Erik and Svensson, Åke LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- EJD. European Journal of Dermatology
- volume
- 22
- issue
- 2
- pages
- 238 - 245
- publisher
- John Libbey Eurotext
- external identifiers
-
- wos:000302908700014
- pmid:22361745
- scopus:84859755815
- pmid:22361745
- ISSN
- 1167-1122
- DOI
- 10.1684/ejd.2011.1635
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Dermatology and Venerology (013241320)
- id
- a87886c3-82ce-4976-bea4-800b8ed7635a (old id 2432544)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22361745?dopt=Abstract
- date added to LUP
- 2016-04-04 09:12:14
- date last changed
- 2022-03-15 18:10:01
@article{a87886c3-82ce-4976-bea4-800b8ed7635a,
abstract = {{Objectives: Knowledge of the societal costs of psoriasis is limited. This study estimated the cost of care, psoriasis area and severity index (PASI), and quality of life in a defined patient population in Sweden. Methods: A prevalence-based prospective recruitment of patients visiting two Swedish dermatology clinics between September and December 2009 was performed, collecting resource utilization for health care contacts, treatment, travelling, and productivity loss during 1 month. Results: 164 patients were included. Mean total cost per patient-month was 994€. Main cost drivers were outpatient visits and light therapy (49%), biological drugs (20%) and productivity loss (22%). Total cost for topical treatment only (TT; 34%) was 369€, light therapy (LT; 24%) 1,274€, traditional systemic treatment (TST; 26%) 1,085€ and biological systemic treatment (BST; 16%) 1,709€ per patient-month. Main cost drivers were: outpatient visits (56%) in TT as well as for LT (78%), productivity loss (40%) in TST, and biological drugs (71%) among BST patients. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. Conclusions: The one-month cost-of-illness amounted to almost 1,000€/month, with great variations. Despite 1,190€ difference in drug cost for TST vs BST, total cost per month differed by 623€ because of offsets from improved productivity. A trend towards lower severity and reductions in outpatient and topical treatment costs was seen.}},
author = {{Ghatnekar, Ola and Ljungberg, Anders and Wirestrand, Lars-Erik and Svensson, Åke}},
issn = {{1167-1122}},
language = {{eng}},
number = {{2}},
pages = {{238--245}},
publisher = {{John Libbey Eurotext}},
series = {{EJD. European Journal of Dermatology}},
title = {{Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.}},
url = {{http://dx.doi.org/10.1684/ejd.2011.1635}},
doi = {{10.1684/ejd.2011.1635}},
volume = {{22}},
year = {{2012}},
}